- POAI, Helomics builds AI-driven models that predict drug response, patient outcome
- Company tests patient tumor, generates comprehensive picture that oncologists use to individualize therapy
- Key to individualized insight is POAI’s Tumor Drug Response Profiling (“TDRP”) platform, NGS-based genomic profiling, unmatched cancer knowledge base
Guided by the mantra that “cancer is personal — we believe therapy should be too,” Predictive Oncology (NASDAQ: POAI) subsidiary Helomics focus on building AI-driven models that will predict drug response and patient outcome of individual tumors. With the largest tumor inventory in the world, POAI leads the way in providing a functional precision medicine approach that harnesses the power of an individual patient’s tumor to personalize their cancer treatment plan.
POAI works closely with oncologists to provide key information to help improve their patients’ odds in their fight against cancer. Helomics current clinical test platform offers a powerful, proprietary approach that tests a patient’s unique tumor, then combines drug-response profiling and genomic profiling of that tumor to generate a comprehensive picture that an oncologist can use to individualize therapy and improve positive outcomes.
Oncologists rely on these personalized profiles to help reduce the risk that a patient receives ineffective therapies as well as to identify alternatives when a typical treatment recommended for certain types of cancer cannot be tolerated.
A key component in Predictive Oncology’s ability to offer such individualized insight is the company’s Tumor Drug Response Profiling (“TDRP”) platform, which it combines with the latest NGS-based genomic profiling and POAI’s vast cancer knowledge-base of 150,000 tumors. Exclusive to POAI, these resources provide a more functional approach to precision medicine and allow an oncologist to reach beyond genomics alone in providing cancer-treatment recommendations.
In addition, every tumor tested by POAI and Helomics adds data to the company’s unparalleled D-CHIP knowledgebase, which contains anonymized molecular and drug-response profiles from more than 150,000 cancer cases. This invaluable information provides researchers in pharma, biopharma and diagnostic companies actionable insights to help discover better targeted therapies as well as contribute to key developments in clinical trials, companion diagnostics, and biomarkers.
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through the company’s Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a road map to help individualize therapy. In addition, the company is utilizing artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow
For more information about the company, visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment